How to Counsel and Monitor Early LAI Treatment in Schizophrenia
How should clinicians counsel and follow patients started on an LAI early after schizophrenia diagnosis given the higher discontinuation risk seen with early initiation?
Early LAI initiation may reduce psychiatric hospitalization burden, but patients who started within the first year in this study had higher discontinuation risk than those who started later. Clinicians need a practical way to set expectations and intensify follow-up when choosing early LAI treatment.
-
Explain the tradeoff between hospitalization benefit and persistence
Tell patients and families that earlier LAI initiation was associated with fewer psychiatric hospitalization days, but not with better treatment persistence in this study. Patients started within 1 year had higher discontinuation risk than those started after 2 years, so early use should be presented as a choice that may require more support rather than as a simpler option.
-
Set follow-up expectations around continuation of LAI dosing
Use the study's discontinuation framework to structure monitoring for persistence: treatment discontinuation was defined as a lapse of more than 28 days after the expected end date of the previous LAI injection. Missing the expected dosing interval by more than 28 days should therefore be treated as a meaningful break in treatment continuity.
-
Monitor especially closely during early-phase LAI treatment
Because later initiators had significantly lower discontinuation hazards than the within-1-year group, clinicians should anticipate that newly diagnosed patients started early may be more likely to stop treatment. The authors note that limited treatment experience and limited adherence education may contribute to this pattern, so early-phase monitoring should be especially deliberate.
-
Reassess persistence concerns without losing sight of hospitalization risk
If a patient is struggling with continuing an LAI started early, weigh that problem against the study's hospitalization findings rather than assuming that delaying or abandoning LAI treatment is preferable. Later initiation was linked to better persistence, but delayed initiation, especially beyond 5 years, was associated with greater hospitalization burden.
-
In hospitalized or more severe patients, favor persistence support over delay
Among patients who had psychiatric hospitalization during LAI treatment, earlier initiation showed a stronger association with lower hospitalization burden. In these patients, the practical response to discontinuation risk is not simply to postpone LAI treatment, but to support continuity while recognizing that delays were associated with worse hospitalization outcomes.
Clinical Considerations
- The study did not test a specific adherence intervention, so this guide can identify who may need closer persistence monitoring but cannot specify an evidence-based follow-up schedule beyond the discontinuation definition used in the article.
- Continuous LAI treatment was inferred from prescription patterns and may not perfectly reflect actual medication receipt or adherence.
- Discontinuation was defined only from LAI administration and did not account for concurrent oral antipsychotic treatment.
- The authors note uncertainty about the optimal duration of maintenance treatment in early schizophrenia, so these findings should not be used to set a fixed maintenance length.
Bottom Line
When starting an LAI within the first year after schizophrenia diagnosis, counsel that hospitalization outcomes may be better but discontinuation risk is higher, and monitor closely for gaps greater than 28 days after the expected injection interval.
